Yuri Tolkach
Yuri Tolkach
Institute of Pathology, University Clinic of Cologne
Verified email at - Homepage
Cited by
Cited by
The heterogeneity of prostate cancer: a practical approach
Y Tolkach, G Kristiansen
Pathobiology 85 (1-2), 108-116, 2018
High-accuracy prostate cancer pathology using deep learning
Y Tolkach, T Dohmgörgen, M Toma, G Kristiansen
Nature Machine Intelligence 2 (7), 411-418, 2020
Quality control stress test for deep learning-based diagnostic model in digital pathology
B Schömig-Markiefka, A Pryalukhin, W Hulla, A Bychkov, J Fukuoka, ...
Modern Pathology 34 (12), 2098-2108, 2021
Comprehensive evaluation of prostate specific membrane antigen expression in the vasculature of renal tumors: implications for imaging studies and prognostic role
S Spatz, Y Tolkach, K Jung, C Stephan, J Busch, B Ralla, A Rabien, ...
The Journal of urology 199 (2), 370-377, 2018
Serum miR-122-5p and miR-206 expression: non-invasive prognostic biomarkers for renal cell carcinoma
FG Heinemann, Y Tolkach, M Deng, D Schmidt, S Perner, G Kristiansen, ...
Clinical epigenetics 10, 1-9, 2018
The N6‐methyladenosine (m6A) erasers alkylation repair homologue 5 (ALKBH5) and fat mass and obesity‐associated protein (FTO) are prognostic biomarkers …
A Strick, F von Hagen, L Gundert, N Klümper, Y Tolkach, D Schmidt, ...
BJU international 125 (4), 617-624, 2020
Systematic analysis of the expression of the mitochondrial ATP synthase (complex V) subunits in clear cell renal cell carcinoma
M Brüggemann, A Gromes, M Poss, D Schmidt, N Klümper, Y Tolkach, ...
Translational oncology 10 (4), 661-668, 2017
Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy
Y Tolkach, H Gevensleben, R Bundschuh, A Koyun, D Huber, C Kehrer, ...
Breast cancer research and treatment 169, 447-455, 2018
P athogenic and targetable genetic alterations in 70 urachal adenocarcinomas
H Reis, KE van der Vos, C Niedworok, T Herold, O Módos, A Szendrői, ...
International Journal of Cancer 143 (7), 1764-1773, 2018
PITX2 DNA methylation as biomarker for individualized risk assessment of prostate cancer in core biopsies
B Uhl, H Gevensleben, Y Tolkach, V Sailer, M Majores, M Jung, S Meller, ...
The Journal of Molecular Diagnostics 19 (1), 107-114, 2017
5′-tRNA halves are dysregulated in clear cell renal cell carcinoma
C Zhao, Y Tolkach, D Schmidt, G Kristiansen, SC Müller, J Ellinger
Journal of Urology 199 (2), 378-383, 2018
Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy
X Chen, C Bernemann, Y Tolkach, M Heller, C Nientiedt, M Falkenstein, ...
Urologic Oncology: Seminars and Original Investigations 36 (4), 161. e19-161 …, 2018
Sensitivity of HOXB13 as a diagnostic immunohistochemical marker of prostatic origin in prostate cancer metastases: comparison to PSA, prostein, androgen receptor, ERG, NKX3. 1 …
I Kristiansen, C Stephan, K Jung, M Dietel, A Rieger, Y Tolkach, ...
International journal of molecular sciences 18 (6), 1151, 2017
Prostate-specific membrane antigen expression in hepatocellular carcinoma: potential use for prognosis and diagnostic imaging
Y Tolkach, D Goltz, A Kremer, H Ahmadzadehfar, D Bergheim, M Essler, ...
Oncotarget 10 (41), 4149, 2019
Luteinizing hormone‐releasing hormone (LHRH) receptor agonists vs antagonists: a matter of the receptors?
Y Tolkach, S Joniau, H Van Poppel
BJU international 111 (7), 1021-1030, 2013
Initial experiences with the Hemopatch® as a hemostatic agent in zero-ischemia partial nephrectomy
F Imkamp, Y Tolkach, M Wolters, S Jutzi, M Kramer, T Herrmann
World journal of urology 33, 1527-1534, 2015
Three‐dimensional reconstruction of prostate cancer architecture with serial immunohistochemical sections: hallmarks of tumour growth, tumour compartmentalisation, and …
Y Tolkach, S Thomann, G Kristiansen
Histopathology 72 (6), 1051-1059, 2018
Systematic expression analysis of mitochondrial complex I identifies NDUFS1 as a biomarker in clear-cell renal-cell carcinoma
J Ellinger, M Poss, M Brueggemann, A Gromes, D Schmidt, N Ellinger, ...
Clinical Genitourinary Cancer 15 (4), e551-e562, 2017
Systematic expression analysis of the mitochondrial complex III subunits identifies UQCRC1 as biomarker in clear cell renal cell carcinoma
J Ellinger, A Gromes, M Poss, M Brüggemann, D Schmidt, N Ellinger, ...
Oncotarget 7 (52), 86490, 2016
YRNA expression predicts survival in bladder cancer patients
Y Tolkach, AF Stahl, EM Niehoff, C Zhao, G Kristiansen, SC Müller, ...
BMC cancer 17, 1-7, 2017
The system can't perform the operation now. Try again later.
Articles 1–20